Insmed Inc. buy stratec
Summary
This prediction ended on 10.06.19 with a price of €21.77. The price of Insmed Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -14.70%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Insmed Inc. | -0.602% | -0.602% | 140.876% | 826.966% |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% | 70.406% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% | 103.787% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% | 45.417% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% | 64.908% |
Comments by stratec for this prediction
In the thread Insmed Inc. diskutieren
stratec stimmt der Outperform-Einschätzung der institutionellen Analysten zu
stratec stimmt am 09.06.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 38.44$ zu.
Insmed has a fairly strong product pipeline with Phase 2 and preclinical stage candidates. The company has strong chances of receiving approval for its ALIS therapy. (Amikacin Liposome Inhalation Suspension)
The drug is designed to treat nontuberculous mycobacterial (NTM),
a lung disease caused by Mycobacterium avium complex. What is even more encouraging is that the drug has been granted Priority Review status and its PDUFA date is set on September 28. The treatment has high probability of being accepted as it showed substantially higher success rate than current therapies for the ailment.
Insmed plans to launch the drug in the market by year-end.